Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress

Liquidia (LQDA) will present two scientific posters at the European Respiratory Society (ERS) 2026 Congress in Barcelona, Spain, held September 5-9, 2026.

Rhea-AI Summary

Liquidia (LQDA) will present two scientific posters at the European Respiratory Society (ERS) 2026 Congress in Barcelona, Spain, held September 5-9, 2026.

The first poster, from the ASCENT study (NCT06129240), covers baseline lung morphology patterns in interstitial lung disease with pulmonary hypertension and will be presented in Poster Session PS-35 on September 7, 2026, 8:00-9:30 CEST by N. Kolaitis (University of California, San Francisco, United States). The second poster describes the Phase 3 Re-Spire trial evaluating safety and efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in pulmonary hypertension with interstitial lung disease and will be presented in Poster Session PS-37 on September 8, 2026, 12:30-14:00 CEST by Prof. V. Cottin (Claude Bernard University Lyon 1, France).

Market Context

LQDA's recent insider records showed 310,635 shares sold and no shares bought. Against that net-sell...

Analysis

LQDA's recent insider records showed 310,635 shares sold and no shares bought. Against that net-selling backdrop, the ERS announcement offered presentation visibility but no reported outcomes; subsequent trial data and regulatory developments remained key risks.

Key Figures

Poster count: 2 posters Congress dates: September 5-9, 2026 Study identifier: NCT06129240 +3 more

6 metrics

Poster count 2 posters ERS 2026 Congress

Congress dates September 5-9, 2026 Barcelona, Spain

Study identifier NCT06129240 ASCENT study

Trial phase Phase 3 Re-Spire study of L606

First poster date September 7, 2026 ASCENT study poster

Second poster date September 8, 2026 Re-Spire study poster

Historical Context

5 past events · Latest: Sep 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 01	Conference participation	Neutral	-1.8%	Executives scheduled a fireside chat at Wells Fargo healthcare conference
Aug 12	2Q26 earnings report	Positive	-10.6%	Reported profitable second-quarter results and YUTREPIA-driven revenue growth
Jul 29	Earnings date notice	Neutral	+0.0%	Scheduled release of second-quarter 2026 financial results
Jun 11	Poster presentations	Neutral	+9.8%	Announced four posters covering ASCENT and related PH-ILD topics
Jun 08	Index inclusion	Positive	+3.3%	Announced inclusion in S&P SmallCap 600 index effective June 22

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent presentation and corporate announcements produced mixed reactions, including a 9.77% gain for prior poster news and a 1.83% decline after conference participation news.

Key Terms

interstitial lung disease, pulmonary hypertension, randomized, double-blinded, +1 more

5 terms

interstitial lung disease medical

"baseline lung morphology in ILD-PH in the ASCENT study"

A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

pulmonary hypertension medical

"patients with challenging respiratory and vascular diseases"

Pulmonary hypertension is a condition where the blood vessels in the lungs become narrowed or stiff, forcing the right side of the heart to work much harder to push blood through—imagine a pump trying to push water through narrower pipes. For investors, it matters because the condition drives demand for diagnostic tests, ongoing treatments, and new drugs; changes in clinical trial results, approvals, or treatment guidelines can meaningfully affect the commercial prospects and costs for companies focused on this disease.

randomized technical

"A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study"

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

double-blinded technical

"Randomized, Double-Blinded, Placebo-Controlled Study"

A double-blinded study is a test where neither the participants nor the people administering the treatments know who is getting which version, so expectations can't influence the results. For investors, that fairness check makes clinical or product test results more reliable—think of it like a blind taste test where both the taster and server are kept unaware—so positive outcomes from double-blinded studies carry more weight for valuation and regulatory confidence.

placebo-controlled technical

"Double-Blinded, Placebo-Controlled Study to Evaluate"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it will present two posters at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.

Dr. Rajeev Saggar, M.D., Chief Medical Officer of Liquidia, said: “These presentations represent important steps in building the evidence around our inhaled treprostinil programs, which have the potential to meaningfully change the treatment experience for people living with pulmonary hypertension with interstitial lung disease.”

Poster Presentations

Patterns in interstitial lung disease: A snapshot of the baseline lung morphology in ILD-PH in the ASCENT study [NCT06129240]
Poster Session: PS-35
Date: September 7, 2026
Time: 8:00-9:30 CEST
Presenter: N. Kolaitis (University of California, San Francisco, United States)

Re-Spire: A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Pulmonary Hypertension With Interstitial Lung Disease, PH-ILD
Poster Session: PS-37
Date: September 8, 2026
Time: 12:30-14:00 CEST
Presenter: Prof. V. Cottin (Claude Bernard University Lyon 1, France)

About YUTREPIA^® (treprostinil) Inhalation Powder
YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. YUTREPIA was designed using Liquidia’s PRINT^® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. YUTREPIA was previously referred to as LIQ861 in investigational studies.

About L606 (liposomal treprostinil inhalation suspension)
L606 is an investigational, extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer. The L606 suspension uses a proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period of time. L606 is currently being evaluated in an open-label study in the United States for treatment of PAH and PH-ILD and is the subject of Re-Spire, a global pivotal placebo-controlled efficacy study for the treatment of PH-ILD.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT^® technology. PRINT enabled the development of YUTREPIA^® (treprostinil) inhalation powder for the treatment of PAH and PH-ILD. The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Contacts:

Investors
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com

Media
media@liquidia.com

FAQ

What did Liquidia (LQDA) announce regarding the ERS 2026 Congress?

Liquidia announced that it will present two posters at the European Respiratory Society (ERS) 2026 Congress in Barcelona, Spain, held September 5-9, 2026, focused on interstitial lung disease and pulmonary hypertension with inhaled treprostinil programs.

When and where will Liquidia (LQDA) present its posters at ERS 2026?

Liquidia’s posters will be presented at the ERS 2026 Congress in Barcelona. The ASCENT study poster is scheduled for September 7, 2026, 8:00-9:30 CEST (PS-35), and the Re-Spire Phase 3 trial poster on September 8, 2026, 12:30-14:00 CEST (PS-37).

What is the focus of Liquidia’s ASCENT study poster at ERS 2026 for LQDA?

The ASCENT study poster, titled “Patterns in interstitial lung disease,” provides a snapshot of baseline lung morphology in interstitial lung disease with pulmonary hypertension (ILD-PH). It is part of Poster Session PS-35 on September 7, 2026, and is linked to study NCT06129240.

What is the Re-Spire Phase 3 trial being presented by Liquidia (LQDA) at ERS 2026?

The Re-Spire poster describes a Phase 3, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in patients with pulmonary hypertension with interstitial lung disease (PH-ILD), presented in Poster Session PS-37.

Who will present Liquidia’s posters at the ERS 2026 Congress for LQDA?

The ASCENT study poster will be presented by N. Kolaitis from the University of California, San Francisco, United States. The Re-Spire Phase 3 trial poster will be presented by Prof. V. Cottin from Claude Bernard University Lyon 1, France.